Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Down 48.9% in August

Posted by George Bondi on Sep 16th, 2026

Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) was the target of a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 25,174 shares, a drop of 48.9% from the August 15th total of 49,268 shares. Approximately 2.5% of the company’s shares are short sold. Based on an average trading volume of 188,915 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Clearmind Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th.

Get Our Latest Stock Report on CMND

Clearmind Medicine Stock Down 6.4%

Shares of NASDAQ:CMND traded down $0.06 during trading on Wednesday, hitting $0.81. The stock had a trading volume of 123,636 shares, compared to its average volume of 1,008,343. The company has a market capitalization of $825,180.00, a PE ratio of -0.02 and a beta of 0.81. The company has a quick ratio of 4.31, a current ratio of 4.31 and a debt-to-equity ratio of 0.01. The firm’s fifty day moving average is $1.65 and its 200 day moving average is $4.71. Clearmind Medicine has a 12 month low of $0.79 and a 12 month high of $524.00.

Clearmind Medicine (NASDAQ:CMND – Get Free Report) last issued its quarterly earnings results on Thursday, September 10th. The company reported ($0.57) earnings per share for the quarter.

Clearmind Medicine Company Profile

(Get Free Report)

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.